Cyclacel Pharmaceuticals held its 2024 Annual Meeting of Stockholders, where stockholders approved an amendment to the company's 2018 Equity Incentive Plan and appointed a new Chair of the board of directors. The company also suspended payment of the quarterly cash dividend on its 6% Convertible Exchangeable Preferred Stock.